دورية أكاديمية
Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study
| العنوان: | Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study |
|---|---|
| المؤلفون: | Carretero Gomez, Juana, Arévalo-Lorido, José Carlos, Gómez Huelgas, Ricardo, García de Lucas, Dolores, Mateos Polo, Lourdes, Varela Aguilar, Jose M., Seguí-Ripoll, José Miguel, Ena, Javier |
| المساهمون: | Departamentos de la UMH::Medicina Clínica |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2018 |
| المجموعة: | RediUMH (Universidad Miguel Hernández) |
| مصطلحات موضوعية: | body weight, glycemic control, glucagon-like peptide-1 receptor agonists (GLP-1ra), older patient, sodium-glucose cotransporter 2 inhibitors (SGLT2i) |
| الوصف: | Objectives: Scientific literature about the combination of glucagon-like peptide-1 receptor agonists (GLP1ra) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in older patients is scarce. We sought to assess the real-world efficacy and safety of SGLT2 inhibitors and GLP-1ra combination therapy in older patients (>65 years of age). Methods: This was an observational, prospective, multicenter study based on clinical practice. Patients were stratified according to tertiles of baseline glycated hemoglobin (A1C) levels and to treatment schedule. Results: We included 113 patients (65.5% men, mean age 70.4±8.8 years). The body mass index was 36.5 (±6.6) kg/m2. The baseline A1C level was 8.0% (±1.2%). At the 6-month follow up, we found a significant reduction in A1C levels (–1.1%; p<0.0001), body mass index (–2.1 kg/m2; p<0.00003) and systolic blood pressure (–13 mmHg; p<0.000005). Patients who had the highest baseline A1C levels (≥8.4%) showed greater improvement in A1C levels (p<0.0001), weight (p<0.0001) and quality-of-life scores (p<0.0001). The greatest reduction in A1C levels and weight was seen in patients who started both drugs simultaneously (p<0.0001). The second greatest reduction was seen when GLP-1ra was added to previous treatment with an SGLT2i (p<0.0001). Also of note was a decrease in systolic blood pressure in patients for whom an SGLT2i was added to previous GLP-1ra treatment (p<0.0001). Of the patients, 34.3% achieved the combined endpoint of A1C levels <7% and weight loss ≥5% without hypoglycemia. Conclusions: This study’s findings provide evidence of clinically meaningful reductions in A1C level, body weight and systolic blood pressure in older patients with type 2 diabetes who are taking combined regimens. The dropout and hypoglycemia rates were minimal, and treatment was tolerated well. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2352-3840 1499-2671 |
| العلاقة: | https://doi.org/10.1016/j.jcjd.2018.09.001Test; Canadian Journal of Diabetes. 43(2019) 186-192; https://hdl.handle.net/11000/31198Test |
| الإتاحة: | https://doi.org/10.1016/j.jcjd.2018.09.001Test https://hdl.handle.net/11000/31198Test |
| حقوق: | info:eu-repo/semantics/closedAccess ; Attribution-NonCommercial-NoDerivatives 4.0 Internacional ; http://creativecommons.org/licenses/by-nc-nd/4.0Test/ |
| رقم الانضمام: | edsbas.2F67DFEE |
| قاعدة البيانات: | BASE |
| تدمد: | 23523840 14992671 |
|---|